Justin Chukma
Chief Business Officer
Replay available
ARS Pharmaceuticals, Inc. (SPRY) Q4 2025 Earnings Call
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) Q4 2025 earnings conference call, held 2026-03-09. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Richard Lowenthal
Co-Founder, President, and CEO
Eric Karras
Chief Commercial Officer
Kathy Scott
Chief Financial Officer
Maria-Lena Smallfin
Analyst
Kevin Holder
Analyst, Broad Capital Partners
Lachlan Hanbury-Brown
Analyst, William Blair
Unidentified Participant
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Ars Pharmaceuticals, Inc..
Replay transcript excerpt
WEBVTT 00:00:01.482 -- 00:00:06.532 Good morning and welcome to ARS Pharmaceuticals' fourth quarter and full year 2025 00:00:06.532 -- 00:00:11.902 earnings conference call. At this time, all participants are in a listen-only mode. 00:00:11.902 -- 00:00:16.391 After the company's prepared remarks, we will open the line for questions. 00:00:16.391 -- 00:00:19.697 Please be advised that today's conference is being recorded. 00:00:19.697 -- 00:00:23.805 I will now turn the call over to Justin Chukma, Chief Business Officer. 00:00:23.805 -- 00:00:26.286 Please go ahead. 00:00:27.166 -- 00:00:31.533 Good morning and thank you for joining our fourth quarter and full year 2025 earnings 00:00:31.533 -- 00:00:36.240 conference call. With me on the call are Richard Lowenthal, our co-founder, president, 00:00:36.240 -- 00:00:41.728 and CEO, Eric Karras, our chief commercial officer, and Kathy Scott, 00:00:41.728 -- 00:00:44.272 our chief financial officer. 00:00:44.272 -- 00:00:48.519 Earlier this morning, we issued a press release detailing our financial results and commercial 00:00:48.519 -- 00:00:53.018 highlights for the fourth quarter and full year 2025. 00:00:53.018 -- 00:00:58.185 That press release and the slide presentation that we will refer to during today's call 00:00:58.185 -- 00:01:02.370 are available in the Investors and Media section of our website. 00:01:02.370 -- 00:01:07.497 Before we begin, please note that today's remarks may contain forward-looking statements. 00:01:07.497 -- 00:01:12.824 Actual results may differ materially. Please refer to our press release and SEC filings 00:01:12.824 -- 00:01:18.411 for further risk disclosures. With that, I'll turn the call over to Rich. 00:01:18.411 -- 00:01:22.415 Thank you, Justin. Good morning, everybody, and tha...